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Abstract 
Background: Blockage of some ion channels and in particular, the hERG (human Ether-a`-go-
go-Related  Gene)  cardiac  potassium  channel  delays  cardiac  repolarization  and  can  induce
arrhythmia. In some cases it leads to a potentially life-threatening arrhythmia known as Torsade
de Pointes (TdP). Therefore recognizing drugs with TdP risk is essential. Candidate drugs that
are determined not to cause cardiac ion channel blockage are more likely to pass successfully
through clinical phases II and III trials (and preclinical work) and not be withdrawn even later
from the marketplace due to cardiotoxic effects. The objective of the present study is to develop
an  SAR  (Structure-Activity  Relationship)  model  that  can  be  used  as  an  early  screen  for
torsadogenic (causing TdP arrhythmias) potential in drug candidates. The method is performed
using  descriptors  comprised  of  atomic  NMR  chemical  shifts  (13C  and  15N  NMR)  and
corresponding interatomic distances which are combined into a 3D abstract space matrix. The
method  is  called  3D-SDAR  (3-dimensional  spectral  data-activity  relationship)  and  can  be
interrogated to identify molecular features responsible for the activity, which can in turn yield
simplified hERG toxicophores.  A dataset of 55 hERG potassium channel inhibitors collected
from Kramer et al. consisting of 32 drugs with TdP risk and 23 with no TdP risk was used for
training the 3D-SDAR model. 
Results: An artificial  neural  network (ANN) with  multilayer  perceptron  was  used  to  define
collinearities among the independent 3D-SDAR features. A composite model from 200 random
iterations with 25% of the molecules in each case yielded the following figures of merit: training,
99.2 %; internal test sets, 66.7%; external (blind validation) test set, 68.4%. In the external test
set,  70.3%  of  positive  TdP  drugs  were  correctly  predicted.  Moreover,  toxicophores  were
generated from TdP drugs.
Conclusion: A 3D-SDAR was successfully used to build a predictive model for drug-induced
torsadogenic and non-torsadogenic drugs based on 55 compounds. The model was tested in 38
external drugs.
Keywords: Artificial  Neural  Network;  Cardiac  Arrhythmia;  Cardiotoxicity;  hERG;  Ion
Channels;  Multilayer  Perceptron;  Quantitative  structure-activity  relationship,  Spectral  data-
activity relationship, Torsade de Pointes; TdP.
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Background
Potassium plays  a  crucial  role  in  the  cardiovascular  system.  The  flow  of  potassium  across
cardiomyocytes  is  essential  for  cardiac  rhythm.  A  number  of  compounds  block  cardiac
potassium ion channels and cause arrhythmia.  Cardiac potassium channels have an important
role  in  ischemic  pre-conditioning.  Among  these  channels,  the  ATP  sensitive  potassium ion
channels which are ligand-gated channels can be abundantly found in all regions of the heart
(Grant, 2009).  Figure 1 illustrates schematic changes in voltage (cardiac membrane potential)
across the cardiomyocytes. After potassium ions begin to flow into the myocytes, calcium and
potassium ions offset each other, which produce a plateau phase. Further, after efflux of more
potassium ions  outside  the  myocytes,  repolarization  will  take  place.  Repolarization  involves
interactions among numerous calcium, sodium, and potassium channels. Nevertheless, potassium
channels  play  a  key  role  in  a  type  of drug-induced  cardiac  arrhythmia  and  may  lead  to  a
potentially life-threatening condition termed “Torsade de Pointes” (TdP). The lower green arrow
in Figure 1, indicates a longer action potential (320 milliseconds). QT prolongation is a special
cardiovascular safety concern. The QT interval characterizes the time from the depolarization to
ventricular  repolarization,  and  its  elongation  causes  cardiac  arrhythmia  (Villoutreix  and
Taboureau, 2015). 
To our knowledge, 80 voltage-gated potassium-channel families have been recognized in the
human genome (Wulff et al., 2009; Szabò et al., 2010; http://vkcdb.biology.ualberta.ca/). Based
on structure and function, potassium channels generally are separated into the following major
categories:  the  voltage-gated  channels  with  six  transmembrane  domains;  inwardly  rectifying
channels  with  two  transmembrane  domains;  and  Tandem  Pore  channels  with  four
transmembrane domains (Buckingham et al., 2005). The hERG-gene and similar variants are the
most common potassium ion channels in mammals. Blockage of the hERG potassium channels
can act as a trigger to cause syncope and sudden death in rare cases  (Glassman and Bigger,
2001). The level of inhibition of the hERG gene is one of the earliest preclinical markers used to
predict the risk of a compound causing TdP (Mirams et al, 2011).
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Figure 1. Schematic changes in ventricular action potential  at the molecular level within the
cardiomyocytes. The resting membrane potential of cardiomyocytes is about -90 millivolt (mV)
while at the full depolarization it can be gradually shifted to +20 mV. In the repolarization stage,
membrane potential will return to -90 mV. Some drugs can prolong the duration of normal action
potential  (lengthened  action  potential  in  green)  which  eventually  can  lead  to  drug-induced
arrhythmia. Consequently, production of lengthened action potential (long QT syndrome) may
initiate TdP arrhythmia (Adapted with permission from Sharifi, 2017).
As stated earlier, drug-induced blockade of the cardiac ion channels, especially hERG potassium
channel delays cardiac repolarization and causes cardiac arrhythmia, that occasionally causes a
potentially life-threatening arrhythmia (TdP), observed as “twisted points” (French “Torsade de
Pointes”) on the electrocardiogram (Figure 2). TdP is a particular type of atypical heart rhythm
that can lead to ventricular fibrillation and sudden cardiac death. In the past, TdP was observed
idiosyncratically,  only after  a  large  number  of  patients  were exposed to  a  new drug. In  the
electrocardiogram presented on Figure 2, the patient was on therapeutic dose of methadone with
a low serum potassium level of 3.1 mmol/L (normal level = 3.5-5.0 mmol/L). The adverse event
(QT prolongation and in some cases TdP) was reported in a study by Pearson and Woosley
describing a total of 5,503 reports of adverse events associated with methadone (43 patient noted
the  occurrence  of  TdP  and  16  patients  QT  prolongation)  (Pearson  and  Woosley,  2005).
Methadone is metabolized in hepatocytes primarily by cytochrome P450 (CYP3A4) (Ferrari et
al.,  2004).  A  methadone  derivative,  levacetylmethadol,  was  withdrawn  from  the  European
market after being associated with TdP. Pearson and Woosley reported a case that drug-drug
interactions  between  nelfinavir  (a  potent  CYP3A4  inhibitor)  and  methadone  initiated  TdP
(Pearson and Woosley,  2005). To date,  not many studies have been conducted on drug-drug
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interactions  between methadone and other  drugs and their  association with TdP arrhythmias.
However  this  type  of  interaction  leading  to  TdP  is  well  documented  for  cisapride  and
terfenadine.  Both drugs are associated with prolonged ventricular repolarization,  high-affinity
blockade inside the hERG cavity, but rarely causing sudden death (Wysowski and Bacsanyi.,
1996; Monahan et al., 1990). Methadone is also presented in the dataset used in this study (where
its TdP risk was correctly predicted as positive).
More recently, detection of an important indicator of proarrhythmic liability became possible in
potential drug candidates. Also, once the mechanism relating potassium channel blockage to TdP
was realized, the US Food and Drug Administration (FDA) added possible or high risk for TdP
as a safety criterion for new drug applications (Kerns and Di, 2008). Compounds with hERG
blocking liability might fail during preclinical and costly clinical trials. Hence, understanding the
molecular  mechanisms  involved  in  binding  of  drugs  to  hERG  channels  and  drug  risk
identification  from  channel  blockage  is  now  considered  essential  for  both  pharmaceutical
companies  and regulatory authorities.  Numerous approved drugs  such as  the aforementioned
terfenadine (antihistamine) and cisapride (a gastroprokinetic agent) were eventually recalled due
to cardiac toxicity associated with blockade of hERG channel (Yap and Camm, 2003). It is well-
established that the majority of potential hERG blockers prolong QT, but the converse is not so.
There are a few drugs that  block hERG channels  without  causing TdP. Verapamil,  a potent
hERG channel blocker is not associated with TdP (Martin et al., 2004). Further, even though all
drug-induced torsadogenic compounds have a low IC50 (strong blockers of hERG), not all hERG
blockers with strong potencies lead to TdP. For example, ranolazine is an hERG channel blocker
and prolongs QT, but appears not to cause arrhythmia, due to the effects on late sodium currents
(Stockbridge et  al.,  2013).  Mirams and his colleagues,  tested multiple  ion channel  blockage,
namely, sodium calcium and potassium channels for prediction of TdP (Mirams et al., 2011).
They  collected  31  drugs  associated  with  varied  risks  of  TdP,  and  applied  numerous  pacing
protocols  for  simulation  purposes.  They  concluded  that  consideration  of  hERG  blockade  is
necessary, but not sufficient, to predict torsadogenic risk (Mirams et al., 2011). 
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Figure 2. A 12-lead electrocardiogram represents a long QT syndrome in in a 49-year-old male
on  therapeutic  dose  of  methadone  with  a  serum  potassium  level  of  3.1  mmol/L  and  no
cardiovascular disease history seen in the patient’s family. A burst of TdP can be seen on the left,
and  short  time  (under  ten  seconds)  tachycardia  can  be  seen  on  V1-V6  (right).  The
electrocardiogram is used with the permission of Dr. Pierre Taboulet (Taboulet, 2017).
Computational  models  can  be  used  as  an  early  screen  for  torsadogenic  potential  in  drug
candidates. SAR studies of hERG models as well as structure modification strategies are being
developed and they aim to reduce the risk of hERG blockage. Numerous models have been built
to profile potential hERG channel blockage of newly discovered compounds. Indeed, applying in
silico tools  is  an  emerging  trend  for  screening  and  detecting  potential  inhibitors  of  hERG
channels (Kerns and Di, 2008). Sanguinetti and Mitcheson studied how drugs bind as residues
lining the central cavity of the hERG channel and suggested in silico approaches to assess hERG
channel  blockade  (Sanguinetti  and  Mitcheson,  2005).  Results  of  their  models  based  on
physicochemical  properties of chemical structures used in the training set of an SAR model,
indicate that electrostatic groups in the para position of phenyl rings and hydrophobic bulk on the
tail  of  compounds  both  can  influence  drug  affinity  for  the  hERG channel  (Sanguinetti  and
Mitcheson, 2005). In a recent study by Stoyanova-Slavova and co-workers, 237 compounds and
their  corresponding  hERG  channel  activities  were  collected  from  22  databases,  and  some
classification models using partial least squares (PLS) regression were built where four latent
variables  used  for  reporting  the  results  (Stoyanova-Slavova  et  al.,  2017).  The  best  model
successfully predicted the hERG activities with an overall prediction accuracy of 0.84 for both
external and internal validation sets. However, in the external (blind) test set of their models, 10
out  of  16  hERG active  compounds  were  predicted  incorrectly.  Further,  the  most  important
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features obtained from PLS model were mapped based on PLS weights, and from these hERG
pharmacophores  were obtained.  The diagnostically  most significant  endpoint  for this  area of
modeling is TdP risk, not merely hERG binding.
The objective  of  the  present  study is  to  develop an  SAR-like model  based  directly  on TdP
clinical adverse events, a model that can be used as an early screen for torsadogenic potential in
drug candidates. The less familiar method is called 3D-SDAR and uses descriptors comprised of
NMR chemical  shifts  (13C and  15N) and their  corresponding interatomic  distances  which  are
combined into a 3D abstract space matrix. Such models can be interrogated to identify molecular
features responsible for the activity. If based on hERG blockage data, they can yield simplified
toxicophores for potent inhibitors of hERG potassium cardiac ion channels. If, as in this work,
the models are based directly on TdP data, they should yield toxicophores for TdP. Alternative
modeling approaches included SAR and QSAR techniques embodied in commercial  software
packages.
Methods
Dataset 
The 55 compounds used for  training  and internal  test  sets  were obtained from the literature
(Kramer  et  al.,  2013),  which  include  32  torsadogenic  and  23  non-torsadogenic  drugs  from
multiple classes. The drug-induced torsadogenic risk of each drug for training and internal test
sets presented in this paper (55 drugs), were originally evaluated based on the classifications
assigned in Redfern et al. and the Arizona Center for Education and Research on Therapeutics
(ACERT, www.azcert.org). Torsade risk results for all of the 55 compounds were from a single
lab (Chan Test Corporation, Ohio). A subsampling technique was used for defining training and
internal  validation  sets  in  the  ANN,  with  200  epochs,  which  means  our  aggregate  model
presented the median of predictions from the 200 individual models. Further, to find a dataset for
an external  test  set  (a “blind” validation exercise),  the Essential  Drug Safety Resource from
PharmaPendium’s advanced search engine (www.pharmapendium.com) was used and a total of
527 reports for individual compounds associated with drug-induced TdP arrhythmia were found.
Further, these compounds were filtered and only compounds with more than 25 post-marketing
reports  (defined by the Adverse Event Reporting System (AERS)) on TdP arrhythmias were
retained. For example, warfarin (anticoagulant) was reported to be associate with TdP in only
five cases,  which due to  the low number of reports,  authors  assume that  the TdP caused is
possibly either due to other medications that patients had or because of warfarin’s drug-drug
interactions with other drugs that patient used concurrently. As a result of final filtering, 38 drugs
(out of 527) were retained and were selected to be used in the external test set. The drugs used in
this study for modeling purposes and their TdP risk are listed in Supplementary Table 1.
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Data preparation process
For  each  compound  in  any  of  the  data  sets,  a  3D  mol  file  was  downloaded  directly  from
ChemSpider  (http://www.chemspider.com/),  cleaned  and  geometrically  optimized.  Energy
minimization  was  applied  using  the  AM1  semiempirical  Hamiltonian  provided  by  MOE
software, version 2016.08 (Chemical Computing Group, Montreal, CA). Then the mol files were
imported  into the ACD/NMR predictor  (version 12, ACD/Labs Toronto,  Canada),  with each
molecule’s atom numbering system preserved. The NMR spectra of the compounds in the dataset
were generated  using the HOSE algorithm (Bremser,  1978; Meiler  et  al.,  2002).  The HOSE
algorithm prediction uses a 2D substructural unit. When these shifts for atom pairs in a molecule
were  combined  with  corresponding  interatomic  distances,  the  abstract  pattern  became  3
dimensional  and  in  that  way  reflects  that  molecule’s  Cartesian  3D  nature.  Distances  were
calculated from 3D mol files using an in house program written in R and facilitated with R studio
(Wilkes et al., 2016). NMR chemical shifts for atoms of interest for 13C and 15N were obtained in
the  Spectrus  software  package  (ACD/Labs  package,  Toronto,  Canada)  and  used  as  the
electrostatic component of the SDAR molecular descriptors. 
Binning parameters and fingerprint construction in R
The carbon to nitrogen bin width ratio was set to 2.5 (using 2.5 times C’s bin width). Regarding
bin occupancy range, for nitrogen, a shielding range between -356 and -11 PPM, width = 345
PPM and with a midpoint of -183.5 was considered. For carbon, shielding range varied from -4
to +204 PPM, width = 208 PPM and a midpoint of 100. Figures S1 and S2 in Supplementary
Material  illustrate  carbon  and  nitrogen  shift  frequencies,  respectively,  for  the  initial  55
compounds.  The NMR chemical  shifts  are  expressed  in  parts  per  million  (PPM) units  with
positive values for carbon and negative values for nitrogen. Supplementary Figure 1 shows the
distribution  of  NMR chemical  shifts  for  carbon and nitrogen.  The  frequency  of  interatomic
distances  between atoms in all  molecular  structures  used in training the models  is  shown in
Supplementary Figure 2.  Further, to generate the feature matrix, descriptors were first scaled in
R studio, and then binned. For statistical analysis, the data were imported into Statistica Data
Miner version 11 (StatSoft, Tulsa, OK) to be modeled using its artificial neural network (ANN)
algorithm. Based on the original dataset (Kramer et al., 2013), activities of drugs were assigned
to “1” for drugs with risk of TdP or “0” for drugs that do not cause TdP. In the ANN, activities
were input, and binned numerical values obtained from NMR chemical shifts and interatomic
distances constituted descriptor vectors for each molecule.                                                           
Selection of neural network parameters 
Neural  networks  are  non-parametric  modeling  tools  and use a  series  of  weights  and hidden
neurons to capture complex correlation between the predicted inputs and target variables. We
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used a Multilayer Perceptron (MLP) as multi layered feed forward neural network type with the
gradient descent algorithm in the ANN. To explore parameter  choices for hidden and output
neurons,  the  following  activation  functions  were  examined:  1.  Identity  function  (with  this
function, the activation level is passed on directly as the output); 2. Hyperbolic Tanh (which is a
symmetric S-shaped (sigmoid) function whose output lies in the range of -1 to +1). The number
of layers for the network was set to 2 and the learning rate was set to 0.1. The error functions
were specified to be used in the training network and were calculated by sum of square (given by
the sum of differences between the target and prediction outputs defined over the training set)
using the following equation: Error = ∑ (yi - ti)2  where yi is the prediction (network outputs) of
the target value ti and target values of the  ith data point (Hill and Lewicki., 2006). In order to
avoid overfitting, the “weight decay” option and advanced stopping conditions were enabled in
Statistica to improve generalization performance.
3D Toxicophore identification for TdP Arrhythmias
Detecting the key features (so called toxicophores) associated with a biological activity entails
encoding chemical structural features which can be abstracted into a 3D space matrix.  Since
toxicophore schemes are sensitive to the protonation state of the molecules, strong acids or bases
were deprotonated. For similar reasons, we chose the “enumerate tautomers” option for the weak
acids and bases. The prepared structure of mol files were ionized at  neutral  pH (7.0) before
generating toxicophores.  
Generating Toxicophore using MOE software
3D toxicophore generation  is  an essential  step used in feature identification of active  (drug-
induced torsadogenic) drugs. To build a Toxicophore Query to match a set of torsadogenic drugs,
there is an assumption that all of the molecules bind in a similar conformation to the receptor, a
query  that  represents  a  toxicophore  hypothesis.  A Query  is  a  collection  of  features,  feature
constraints,  and volume restrictions  that  is  applied  to  the  annotation  and atoms of  a  ligand
conformation (Molecular Operating Environment, MOE, 2017). Firstly, mol files for all of the
potential cardiac ion channel inhibitors (all drugs in the dataset causing TdP arrhythmias) were
copied  to  MOE  window,  and  then  we  ran  the  Flexible  Alignment  and  obtained  seven
conformations where the amines and rings were overlaid. Later, using the Consensus option in
the toxicophore query editor, we selected the features which matched all the molecules. 
 
Generating a Toxicophore in Schrödinger suite
Similar  to  MOE,  a  3D database  that  includes  toxicophore  information  was prepared  first  in
Maestro interface (version 10.6; https://www.schrodinger.com/maestro), and then we searched
the  database  for  matches.  Then  to  identify  features  using  Phase  (Schrödinger’s  toxicophore
generation module) the hydrophobic groups, hydrogen bond donors and acceptors, and aromatic
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rings  were  used  as  elements  of  a  “hypothesis”.  Then,  a  common  scaffold  alignment  was
performed  among  the  active  drugs  where  structures  were  aligned  on  the  scaffold,  with
conformational  variation  of  the  side  chains.  In  this  way,  a  hypothesis  finding  common
toxicophores was created and scored. Finally, a toxicophore was generated from the common
toxicophore hypotheses and using the top alignment scores. 
Generating a Toxicophore using a Feature (important bins) Visualizer for 3D-SDAR  
Significant bins obtained from the ANN model were projected onto 3D molecule diagrams using
scripts in R studio, where NMR chemical shifts (representing electrostatic information) together
with interatomic distances (steric information) were combined and tessellated into a 3D abstract
matrix. In this way, visualized data was interrogated to identify molecular features responsible
for  the  activity.  Unlike  the  other  two  methods,  3D-SDAR  fingerprints  are  invariant  under
rotation  of  the  Cartesian  coordinates  and  therefore  independent  of  an  assumed  relationship
between each ligand and it’s hypothetical fit into a biological receptor.
Results and Discussions
In Statistica,  the output summary shows the number of hidden units  each network had; test,
training and validation performance (percentage of compounds predicted correctly); and test and
training  error  values.  Based  on  confusion  matrix,  average  (200  iterations,  hence  200  ANN
models)  of  correctly  predicted  drugs  in  training,  internal  and external  (blind)  test  sets  were
99.2%, 66.7% and 68.4% respectively. In the external (blind) test set, 70.3% of positive TdP
drugs (drugs that are causing TdP arrhythmias) were correctly predicted. The ratio of correctly
predicted  for  the  active  drugs  in  the  dataset  is  utmost  important,  because  toxicophores  are
constructing and mapped from active drugs in the dataset only, therefore, to have a robust model
that later can be used to construct toxicophores, the ratio of correctly predicted “active” drugs
(i.e. TdP+) must always be considered.
Results  of  the  aggregated  predictions  for  all  200  ANN  3D-SDAR  models  can  be  seen  in
Supplementary  Table  2,  where  values  highlighted  in  red  represent  those  which  predicted
incorrectly. Further we performed sensitivity analysis based on ANN results, which shows how
strongly  certain  variables  affected  the  particular  network.  In  a  sensitivity  analysis  summary,
variables  are  sorted  by  sensitivities  (so  the  first  variable  has  the  highest  sensitivity  and
contributed most to the particular network). The significant variables later were loaded in the
Feature  (bins)  Visualizer  application  as  part  of  the  process  by  which  toxicophores  were
constructed. 
Receiver  Operating  Characteristic  (ROC)  curves  are  widely  used  as  a  tool  to  evaluate
classification models. An ROC curve represents the quality of models by visualizing the "true"
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positive versus the "false" positive rate. Figure 3 depicts the 200 ANN models for training, test,
and validation sets. The best models show an ROC curve that approaches the left and top axes in
the  plot.  The blue  curves  are  so colored  to  indicate  a  large  number  of  overlaps  – the  most
characteristic results.
Receiver Operating Characteristic (ROC) Curve
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Figure 3. The ROC curves (cumulative) of SDAR for the training, test and validation (38 blind
hold-out test drugs) sets. The majority of these models (overlapped blue lines) indicated good
predictive accuracy. The lines closer to the diagonal obviously come from the predictions in the
internal and external training sets, less accurate than those of the training sets.
Additionally, to have a better understanding of classification output, we classified the results on a
gain plot. The gain plot shows how well a model correctly classifies a category. The larger the
area  between  the  baseline  (blue)  and  the  line  for  the  predictive  model  (red)  is,  the  better
predictive  accuracy  can  be  obtained.  Gain  is  calculated  as  the  ratio  of  accurately  predicted
compounds to the total number of compounds. Supplementary Figures 3 and 4 show the gain
charts for non-torsadogenic and drug-induced torsadogenic drugs, respectively. Comparing the
two figures  we see  a  better  classification  was  obtained  for  non-torsadogenic  drugs  than  for
torsadogenic drugs. If the imbalance in the training set almost 60% torsadogenic compounds)
were reflected in the predictions, one would have expected a substantial majority of torsadogenic
predictions, which is not indicated in these figures. It is likely, therefore, that the toxicophores
derived from the 3D-SDAR models accurately reflect the features responsible for TdP and are
not simply artifacts of a statistical phenomenon, the training set imbalance.
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Mapping and Investigation of Toxicophores
In MOE, toxicophore consensus creates a list of suggested features from a set of torsadogenic-
conformations of drugs. Figure 4 shows five of the most important  features for active drugs
(drugs with TdP risk) in the dataset.
             
Figure  4. “Mesh globes”  in  the  figure  indicate  the  frequency with  which  that  toxicophores
appears  in  drugs  associated  with  TdP  risk.  Each  globe  can  be  thought  of  as  a  possible
toxicophore in a“3D Query panel” (MOE software). Features #1 and #2 represents two planar Pi
rings. Feature #3 (green) illustrates a hydrophobic centroid (Hyd) and features #4 elucidates a
Polar-Charged-Hydrophobic scheme assigns the label Aro (aromatic center) to a hydrophobic
area. Feature #5 (F5) shows a cationic atom and a H-bond donor. Identification of these five
features is not dependent on any of normal QSAR modeling. Therefore, the fact that these show
up with some frequency in a subset of the data that includes only TdP positive compounds may
or may not indicate that they are necessary participants causing TdP.
Some  antipsychotic  drugs  such  as  clomipramine,  nortriptyline  and  desipramine  (tricyclic
antidepressants), have a cyclopentazepine feature and all are categorized as drugs with possible
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TdP risk based on ongoing systematic analysis of all available evidence stratified for AZCERT
(http://www.azcert.org, as of May 2017). Since these three compounds were not included in the
dataset of this study, some of the potential toxicophores (see F1, F2 and F4 in Figure 4) produced
by  our  models  could  signal  molecular  characteristics  that  may  indicate  a  problem  –  here
likelihood of causing TdP. 
An early hERG pharmacophore was introduced by Ekins and co-workers, with 15 compounds
collected from the literature where four hydrophobes and a positively ionizable feature,  with
approximate distances between the positive center and the hydrophobes of 5-7 angstroms was
proposed (Ekins et al., 2002). More recently, a catalyst hERG pharmacophore model (based on
18  publicly  available  hERG  blockers)  with  a  positive  ionizable  feature,  one  aromatic
hydrophobic and two hydrophobic features was generated (Kratz et al., 2014).
Aligned TdP drugs with their correspondent toxicophores are illustrated in Figure 5. These mesh
globes are similar to but not identical with the ones discussed above.
                    
Figure  5. Visualization  of  the  alignment  of  structures  in  the  59 active  TdP drugs  from the
modeling or external validation sets studied here. The visualization comes from MOE software.
The  TdP  positive  drug  molecules  were  aligned  with  respect  to  their  potential  toxicophores
identified in Figure 4.
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Common toxicophores obtained from Phase (Schrödinger) is shown in Figure 6 depicting three
most important features on the structures (an aromatic ring in orange, an oxygen acceptor (red)
and a hydrophobic atom in (green)).
                 
Figure  6. Shown  is  the  “Common  Toxicophore”  from  Phase  (Schrödinger’s  toxicophore
generation  module)  for three typical  TdP positive compounds.  The Common Toxicophore  is
generated from alignment of all available structures that are positive for causing the effect, here
TdP. An aromatic ring in orange (R13), an oxygen acceptor (A3) and a hydrophobic atom (HB in
green) are identified as important features. These features are selected from a list that includes
the  types  typically  important  in  biological  activity.  The selection  of  the important  subset  of
features does not represent any modeling. Rather they are the features that could be associated
with TdP based on the frequency with which they occur in the data set of known torsadogenic
compounds.
For 3-D SDAR identification of important features might seem similar to the process described
above for MOE and Schrödinger. A significant difference is that “important” SDAR bins are
discovered based not only on their frequency of occurrence in the compound sets but also and
primarily on the statistical weight of their contributions to the SDAR models. 
Three  3D-SDAR  toxicophores  are  constructed  from  the  most  important  predictors  (i.e.
significant  bins)  and  presented  in  Figure  7  overlaid  on  three  representative  TdP  positive
compounds. The toxicophores are characterized by pairs of particular elements with particular
chemical  shifts  and  the  range  of  interatomic  distances.  In  the  case  of  aromatic  rings,  we
recalculate interatomic distances so that they are shown relative to the centroid of the ring, rather
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than  to  its  particular  atoms.  These  toxicophore  components  reflect  contributions  from  all
modeled compounds and reflect the consensus of the 200 ANN models. They are here illustrated
by their superposition as dotted grey lines above a single exemplary molecular structure.   On the
left  feature,  a  benzene  ring  and  a  nitrogen  atom  are  linked  with  7-8  angstroms  distance
(approximately  four  successive  carbon-atoms  long,  which  may  filled  by  other  atoms  in  the
structures). To the best of our knowledge, the earliest hERG pharmacophore was published in
1992 on a class III antiarrhythmic drugs (this pharmacological class typically produce TdP), and
a  simple  pharmacophore  structure  of  a  para-substituted  phenyl  ring  exposed  to  a  nitrogen
(through a four-atoms linking chain)  was obtained from SAR model  (Morgan and Sullivan,
1992;  Chadwick and Goode, 2005).  The middle structure in Figure 7,  demonstrates  a larger
feature  with  two  joint  fragments  (phenylmethanamine  fragment  is  joined  with  a
dimethylethanamine). Feature on the right is a 4-(diphenylmethyl)-piperidine toxicophore with
distances  between  benzene  rings  and  centroid  pyridine  of  4-5  angstroms.  Kramer  and  his
colleagues  collected  113  compounds  from  the  literature  (where  51  compounds  hit  the
pharmacophore)  and generated  several  pharmacophores  for  the  hERG model  (Kramer  et  al.,
2008). In one of the key pharmacophores obtained from their models, two aromatic hydrophobic
features  linked to another  hydrophobic (a ring) feature was observed which is  similar  to the
diphenylmethyl-piperidine obtained from 3D-SDAR in this paper (Figure 7).
 
Figure 7. Most significant  features  identified  by SDAR technique.  The structure on the left
shows a benzene ring and nitrogen atom with a distance of 7-8 angstroms (approximately equal
to a sequential four-atom distance). The middle structure shows a phenylmethanamine fragment
joined with a dimethylethanamine portion. On the right is 4-(diphenylmethyl)-piperidine.
As shown earlier, three different techniques were used for toxicophore mapping in this study.
Toxicophores  in  Figures  4-6  were  obtained  from  traditional  QSAR  techniques  i.e.  flexible
alignment  of  TdP  drugs  followed  by  obtaining  the  pharmacophoric  structural  features  (e.g.
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aromatic ring, hydrophobic areas, charge interactions, etc.) for detection of active drugs, while
constructed toxicophores in Figure 7 were based on the 3D-SDAR technique. Recall  that the
most important selected atoms (atoms of the features presented in Figure 7) are driven directly
from the  most  significant  bins  of  the  model  results,  which  means  they  represent  atom data
(obtained from NMR chemical shifts and their distances between pair of atoms) which shows
importance of those atom pairs in the structures related to their biological activities (here TdP
risk).  Hence,  this  ability  of  the  3D-SDAR model  is  considered  an  advantage  of  3D-SDAR
approach  compare  to  the  traditional  QSAR  pharmacophore  and  toxicophore  identification
techniques. Moreover, unlike QSAR, 3D-SDAR technique can differentiate structural isomers
(compounds with the same formula but different biological activities, e.g. cis-trans or alpha/beta
isomers) because descriptors used in SDAR have different NMR chemical shift information for
different structural isomers. In regards to the diverse set of toxicophore features for TdP risk
from  these  computational  models,  it’s  worth  mentioning  that  the  hERG  binding  pocket  is
promiscuous for drug-like compounds, besides, the binding cavity volume of hERG is also large
(Pearlstein et al., 2003). Another explanation resides in the different ways that the toxicophores
are determined. In the first two cases (MOE and Schrödinger), they are defined only by their
frequency  of  appearance  among  the  available  positive  compounds.  They  are  derived  from
characteristics of the modeling and validation sets and not from the activity models. In the SDAR
case,  a  toxicophore  meets  statistical  criteria  of  association  with  the  compound’s  activity  as
discovered in the models and then, among the features so qualified, a frequency of occurrence
filter is applied.
Nearly  83%  percent  of  all  drugs  in  the  dataset  were  predicted  correctly  (predictions  in
Supplementary  Table  2),  and  only  16  drugs  (out  of  93  drugs  used  in  this  study)  were
misclassified (predicted incorrectly). Considering a very limited sample-size used in this study
(training set  consisted of 43 molecules,  and the internal test  contained 12 drugs only), ANN
performance  of  the  3D-SDAR model  for  both  potential  torsadogenic  drugs  (i.e.,  drugs  with
potential  TdP risk)  as  well  as  the  prediction  accuracy (portion  correctly  predicted)  for  non-
torsadogenic drugs, is considered decent and promising.
Conclusions
The drug-induced cardiotoxic adverse effects with risk of QT prolongation and TdP arrhythmias
signify a major need in clinical studies of drug candidates (Taboureau and Jørgensen, 2011).
Detection  of  compounds  that  potentially  block  the  human  hERG  potassium  channel  is  a
necessary part of the drug safety process because drug-induced QT prolongation caused by these
blockers occasionally appears as an adverse effect of pharmacotherapy. The models were tested
using the external set of 38 drugs with TdP arrhythmias information extracted from patients’
reports from the Adverse Event Reporting System (AERS)) on TdP. The torsadogenic risk of
each drug for training and internal test sets was evaluated based on the classifications assigned as
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explained  by Redfern et  al.,  where zero “0” represents  non-torsadogenic  drugs  and one “1”
denotes  drug-induced  torsadogenic  drugs.  Decent  predicted  values  for  drugs  causing  TdP
arrhythmias and for safe drugs (non-torsadogenic drugs) demonstrate that 3D-SDAR descriptors
have predictive power, which indicates that this 3D-SDAR model contains information linking
of potential inhibitors of hERG potassium channels and TdP. The TdP arrhythmias 3D-SDAR
model provides comparable predictive performance to previously reported QSAR models. 3D-
SDAR modeling was successfully used to build an ANN predictive model of torsadogenicity for
drugs with potassium channel blocking potential. The model developed in this study can be used
to evaluate TdP risk liability and also can be used in virtual screening of libraries to identify
compounds  with  cardiac  toxicophores.  Toxicophores  are  able  to  capture  key  features  and
interatomic  distances  and can be used in  filtering  out  compounds with elevated  risk of TdP
arrhythmias at an initial stage of the drug discovery process (target identification and validation)
to reducing attrition in development in the pharmaceutical industry. Similarities between some of
the hERG pharmacophores discovered using SDAR and published in the literature and those for
TdP presented in this paper are remarkable and may point to the homologous structural functions
within the molecules. On the contrary, a lack of consistency between the TdP features identified
by the three different approaches, suggest that how one finds a toxicophores depends on the way
one searches for it.  Finally,  it  is not unlikely that hERG blockage and TdP may happen via
different mechanisms, and therefore, to assess TdP risk, different computational tools may be
required. 
Future Work and a Limitation 
In terms of hERG blocking potencies and their relevant biological activities, there are large  in
vitro datasets  of  inhibitor/non-inhibitor  type,  some  of  which  are  proprietary  data  and  some
(smaller datasets) are available in the literature. The dataset used in this paper, can be populated
with  more  in  vivo  data  as  they  become available.  This  involvement  of  cutting  edge SDAR
models along with classic QSAR model development, as well as drug-enzyme docking methods
comprises  future  work  in  this  research  study.  In  order  to  further  confirm  the  external
applicability and predictive ability of these TdP risk models, additional compounds will be used
in the external validation set to test the constructed models. A necessary practice in modeling
intended for long term use, is to investigate diversity of the compounds in the dataset and to
define the applicability domain of the models. Furthermore, it will be pertinent to ensure that
datasets are robust with respect to the endpoint values contributing to the models. For instance,
for TdP substrates, the goodness of the methods used for the measurement of activity should be
scrutinized,  and for  model  building,  several  sources  of  data  should be  compared using  only
compounds that have been repeatedly identified in several studies as either positive or negative
for TdP. The idea behind ANNs is inspired by nature, and patterned after the human brain’s
network of neurons. In addition to the computational method used in this study (i.e. ANN), other
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modeling techniques can be used. Examples of such alternatives include PLS (supervised), PLS-
DA (Partial Least Squares Discriminant Analysis), support vector machines and semi-supervised
learning methods.  Semi-supervised learning is  a class  of supervised learning techniques  that
makes  use  of  unlabeled  data  for  training  and has  emerged  as  an  exciting  new direction  in
machine learning research. It can improve models generalizability and applicability by predicting
the values for unknown compounds. Other work could model not only TdP but quantitative risk
of cardiac mortality or frequency of less catastrophic proarrhythmic side effects. 
Among  limitations,  multichannel  blockade  of  channels  in  addition  to  the  potassium cardiac
channel is a recognized phenomenon that would not be reflected in the hERG channel alone.
Sodium and calcium channels (highly localized in the cardiac myocytes) play a key role in the
electrical  excitability  of  cardiomyocytes.  Using  computational  models  for  TdP  risk  with
biological endpoint data obtained from multichannel blockage, should generate more accurate
predictive results than either qualitative TdP or hERG alone. Eventually, multichannel models
may lead to better distinction between safe and unsafe drugs. 
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Materials and Methods:
 
Supplementary Figure 1. Distribution of NMR chemical shifts for carbon (left) and 
nitrogen (right)
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Supplementary Figure 2. Distribution of the interatomic distances between pairs of atoms, 
which play a key role in the formation of SDAR features. 
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Supplementary Figure 3. Gain chart for non-torsadogenic drugs
Supplementary Figure 4. Gain chart for torsadogenic drugs
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